Safety of the Combined Use of Praziquantel and Albendazole in the Treatment of Human Hydatid Disease
| Autor: | Miguel Cordero-Sánchez, Ignacio Novo-Veleiro, Lucía Alvela-Suárez, Ángela Romero-Alegría, Javier Pardo-Lledias, María Paz Valverde-Merino, Moncef Belhassen-García, Luis Pérez del Villar, Virginia Velasco-Tirado |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Disease Albendazole Praziquantel Echinococcosis Recurrence Virology parasitic diseases medicine Humans Adverse effect Aged Retrospective Studies business.industry Standard treatment Retrospective cohort study Articles Middle Aged medicine.disease Magnetic Resonance Imaging Surgery Drug Combinations Treatment Outcome Infectious Diseases Female Parasitology business Adjuvant medicine.drug |
| Zdroj: | The American Journal of Tropical Medicine and Hygiene. 90:819-822 |
| ISSN: | 1476-1645 0002-9637 |
| DOI: | 10.4269/ajtmh.13-0059 |
| Popis: | There is still no well-established consensus about the clinical management of hydatidosis. Currently, surgery continues to be the first therapeutic option, although treatment with anti-parasitic drugs is indicated as an adjuvant to surgery to decrease the number of relapses and hydatid cyst size. When surgery is not possible, medical treatment is indicated. Traditionally, albendazole was used in monotherapy as the standard treatment. However, com- bined therapy with albendazole plus praziquantel appears to improve anti-parasitic effectiveness. To date, no safety studies focusing on such combined therapy have been published for the treatment of hydatidosis. In this work, we analyze the adverse effects seen in 57 patients diagnosed with hydatidosis who were treated with praziquantel plus albendazole combined therapy between 2006 and 2010. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|